Entero Therapeutics, Inc.
ENTO
$1.94
$0.042.11%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -74.05% | -57.91% | 37.06% | 60.16% | 59.82% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -77.28% | -64.71% | -0.95% | 32.63% | 226.89% |
| Operating Income | 77.28% | 64.71% | 0.95% | -32.63% | -226.89% |
| Income Before Tax | 76.51% | 64.14% | 1.11% | -18.15% | -155.45% |
| Income Tax Expenses | -- | 128.64% | -- | -- | -- |
| Earnings from Continuing Operations | -61.91% | -274.38% | 1.11% | 49.48% | -20.44% |
| Earnings from Discontinued Operations | -33.84% | -1,227.23% | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -58.49% | -304.22% | -14.34% | 36.72% | -37.18% |
| EBIT | 77.28% | 64.71% | 0.95% | -32.63% | -226.89% |
| EBITDA | 77.08% | 64.68% | 0.86% | -32.51% | -227.43% |
| EPS Basic | 71.70% | 83.82% | 94.87% | 94.24% | 85.64% |
| Normalized Basic EPS | 98.79% | 97.15% | 92.41% | 87.69% | 76.95% |
| EPS Diluted | 75.75% | 84.58% | 91.77% | 91.86% | 83.06% |
| Normalized Diluted EPS | 98.46% | 96.90% | 97.63% | 92.22% | 81.93% |
| Average Basic Shares Outstanding | 235.88% | 395.83% | 768.52% | 1,187.90% | 1,387.08% |
| Average Diluted Shares Outstanding | -2.49% | -4.68% | 1,688.01% | 2,936.83% | 5,022.58% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |